Assessment of acute coronary syndromes: Focus on novel biomarkers

Current Medicinal Chemistry

Volumn 19, Issue 16, 2012, Pages 2572-2587

  Tousoulis, D ^a   Hatzis, G ^a   Papageorgiou, N ^a   Androulakis, E ^a   Bouras, G ^a   Giolis, A ^a   Bakogiannis, C ^a   Siasos, G ^a   Latsios, G ^a   Antoniades, C ^a   Stefanadis, C ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Acute coronary syndrome; Atherosclerosis; Biomarkers; Ischemia; Myocardial infarction

Indexed keywords

BIOLOGICAL MARKER; CD40 LIGAND; CHOLINE; COPEPTIN; GELATINASE B; HEART FATTY ACID BINDING PROTEIN; ISCHEMIA MODIFIED ALBUMIN; MYELOPEROXIDASE; PLACENTAL GROWTH FACTOR; PREGNANCY ASSOCIATED PLASMA PROTEIN A; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTICLE; ATHEROSCLEROTIC PLAQUE; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; HUMAN; INFLAMMATION; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN FUNCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UNSTABLE ANGINA PECTORIS;

EID: 84860727332     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800493011     Document Type: Article

References (279)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation;121:948-54.
2. Fonarow GC. The global burden of atherosclerotic vascular disease. Nat Clin Pract Cardiovasc Med 2007;4:530-1. (Pubitemid 47490757)
3. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297:1197-206. (Pubitemid 46465728)
4. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-STsegment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002;40:1366-74.
5. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002;23:1809-40.
6. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004;44:E1-E211.
7. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003;24:28-66. (Pubitemid 36109547)
8. Rozenman Y, Gotsman MS. The earliest diagnosis of acute myocardial infarction. Annu Rev Med 1994;45:31-44. (Pubitemid 24158143)
9. Myerburg RJ, Interian A, Jr., Mitrani RM, Kessler KM, Castellanos A. Frequency of sudden cardiac death and profiles of risk. Am J Cardiol 1997;80:10F-9F. (Pubitemid 27377820)
10. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007;116:e148-304.
11. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation 2007;116:2634-53. (Pubitemid 350182388)
12. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43. (Pubitemid 30165206)
13. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of Btype natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7. (Pubitemid 34764819)
14. Mueller C, Laule-Kilian K, Scholer A, et al. Use of B-type natriuretic peptide for the management of women with dyspnea. Am J Cardiol 2004;94:1510-4. (Pubitemid 40268452)
15. Tatum JL, Jesse RL, Kontos MC, et al. Comprehensive strategy for the evaluation and triage of the chest pain patient. Ann Emerg Med 1997;29:116-25. (Pubitemid 27030027)
16. Jesse RL, Kontos MC. Evaluation of chest pain in the emergency department. Curr Probl Cardiol 1997;22:149-236. (Pubitemid 127703803)
17. Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 1996;335:1333-41. (Pubitemid 26360451)
18. Tousoulis D, Kampoli AM, Stefanadi E, et al. New biochemical markers in acute coronary syndromes. Curr Med Chem 2008;15:1288-96. (Pubitemid 351997798)
19. Stefanadi E, Tousoulis D, Papageorgiou N, Briasoulis A, Stefanadis C. Inflammatory biomarkers predicting events in atherosclerosis. Curr Med Chem;17:1690-707.
20. Klebanoff SJ. Myeloperoxidase: contribution to the microbicidal activity of intact leukocytes. Science 1970;169:1095-7.
21. Yamada M. Myeloperoxidase precursors in human myeloid leukemia HL-60 cells. J Biol Chem 1982;257:5980-2. (Pubitemid 12029510)
22. Yamada M, Kurahashi K. Regulation of myeloperoxidase gene expression during differentiation of human myeloid leukemia HL-60 cells. J Biol Chem 1984;259:3021-5. (Pubitemid 14162537)
23. Olsson I, Persson AM, Stromberg K. Biosynthesis, transport and processing of myeloperoxidase in the human leukaemic promyelocytic cell line HL-60 and normal marrow cells. Biochem J 1984;223:911-20. (Pubitemid 15209080)
24. Gullberg U, Bengtsson N, Bulow E, Garwicz D, Lindmark A, Olsson I. Processing and targeting of granule proteins in human neutrophils. J Immunol Methods 1999;232:201-10. (Pubitemid 30017777)
25. Sorensen O, Arnljots K, Cowland JB, Bainton DF, Borregaard N. The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood 1997;90:2796-803. (Pubitemid 27413490)
26. Hurst JK, Barrette WC, Jr. Leukocytic oxygen activation and microbicidal oxidative toxins. Crit Rev Biochem Mol Biol 1989;24:271-328.
27. Nauseef WM, Olsson I, Arnljots K. Biosynthesis and processing of myeloperoxidase-a marker for myeloid cell differentiation. Eur J Haematol 1988;40:97-110. (Pubitemid 18098104)
28. Nauseef WM. Contributions of myeloperoxidase to proinflammatory events: more than an antimicrobial system. Int J Hematol 2001;74:125-33. (Pubitemid 33760061)
29. Tousoulis D, Charakida M, Stefanadis C. Endothelial function and inflammation in coronary artery disease. Heart 2006;92:441-4.
30. Vogiatzi G, Tousoulis D, Stefanadis C. The role of oxidative stress in atherosclerosis. Hellenic J Cardiol 2009;50:402-9.
31. Tousoulis D, Koutsogiannis M, Papageorgiou N, et al. Endothelial dysfunction: potential clinical implications. Minerva Med;101:271-84.
32. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001;286:2136-42. (Pubitemid 34041599)
33. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colonystimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001;158:879-91. (Pubitemid 32221781)
34. Tavora FR, Ripple M, Li L, Burke AP. Monocytes and neutrophils expressing myeloperoxidase occur in fibrous caps and thrombi in unstable coronary plaques. BMC Cardiovasc Disord 2009;9:27.
35. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002;347:5-12. (Pubitemid 34728951)
36. Gerber CE, Bruchelt G, Ledinski G, Greilberger J, Niethammer D, Jurgens G. Low-density lipoprotein modification by normal, myeloperoxidasedeficient and NADPH oxidase-deficient granulocytes and the impact of redox active transition metal ions. Redox Rep 2002;7:111-9. (Pubitemid 34746418)
37. Carr AC, McCall MR, Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol 2000;20:1716-23. (Pubitemid 30470585)
38. Wu J, Liu Y, Li X, Chen L, Xia L, Hong J. The relationship between LDL oxidation and macrophage myeloperoxidase activity. Chin Med J (Engl) 2003;116:791-3. (Pubitemid 36701874)
39. Bergt C, Pennathur S, Fu X, et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A 2004;101:13032-7. (Pubitemid 39167578)
40. Heinecke JW. The role of myeloperoxidase in HDL oxidation and atherogenesis. Curr Atheroscler Rep 2007;9:249-51. (Pubitemid 350081468)
41. Galijasevic S, Saed GM, Diamond MP, Abu-Soud HM. Myeloperoxidase upregulates the catalytic activity of inducible nitric oxide synthase by preventing nitric oxide feedback inhibition. Proc Natl Acad Sci U S A 2003;100:14766-71. (Pubitemid 37517965)
42. Eiserich JP, Baldus S, Brennan ML, et al. Myeloperoxidase, a leukocytederived vascular NO oxidase. Science 2002;296:2391-4.
43. Biasucci LM, D'Onofrio G, Liuzzo G, et al. Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia. J Am Coll Cardiol 1996;27:611-6. (Pubitemid 26080385)
44. Ndrepepa G, Braun S, Mehilli J, von Beckerath N, Schomig A, Kastrati A. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. Eur J Clin Invest 2008;38:90-6. (Pubitemid 351143413)
45. Ferrante G, Nakano M, Prati F, et al. High levels of systemic myeloperoxidase are associated with coronary plaque erosion in patients with acute coronary syndromes: a clinicopathological study. Circulation;122:2505-13.
46. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440-5. (Pubitemid 37176448)
47. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349:1595-604. (Pubitemid 37288567)
48. Morrow DA, Sabatine MS, Brennan ML, et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICSTIMI 18. Eur Heart J 2008;29:1096-102. (Pubitemid 351844877)
49. Mocatta TJ, Pilbrow AP, Cameron VA, et al. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol 2007;49:1993-2000. (Pubitemid 46734639)
50. Khan SQ, Kelly D, Quinn P, Davies JE, Ng LL. Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction. Heart 2007;93:826-31. (Pubitemid 46998982)
51. Mitchell AM, Garvey JL, Kline JA. Multimarker panel to rule out acute coronary syndromes in low-risk patients. Acad Emerg Med 2006;13:803-6. (Pubitemid 43928650)
52. McCann CJ, Glover BM, Menown IB, et al. Investigation of a multimarker approach to the initial assessment of patients with acute chest pain. Adv Ther 2009;26:531-4.
53. Heslop CL, Frohlich JJ, Hill JS. Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography. J Am Coll Cardiol;55:1102-9.
54. Meuwese MC, Stroes ES, Hazen SL, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007;50:159-65. (Pubitemid 47002189)
55. Shih J, Datwyler SA, Hsu SC, et al. Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations. Clin Chem 2008;54:1076-9. (Pubitemid 351793416)
56. Andreou I, Tousoulis D, Miliou A, et al. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. Atherosclerosis;210:194-8.
57. Baldus S, Rudolph V, Roiss M, et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation 2006;113:1871-8. (Pubitemid 43739399)
58. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-39. (Pubitemid 36542523)
59. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002;37:375-536. (Pubitemid 36071972)
60. Katsuda S, Okada Y, Imai K, Nakanishi I. Matrix metalloproteinase-9 (92-kd gelatinase/type IV collagenase equals gelatinase B) can degrade arterial elastin. Am J Pathol 1994;145:1208-18. (Pubitemid 24345668)
61. Vu T.H., Werb Z., 19998. Gelatinase B: structure, regulation and function. In mAtrix Metalloproteinases. W.C. Parks and R.P. Mecham editors, A cademic Press, San Diego. 115-148
62. Zeigler ME, Chi Y, Schmidt T, Varani J. Role of ERK and JNK pathways in regulating cell motility and matrix metalloproteinase 9 production in growth factor-stimulated human epidermal keratinocytes. J Cell Physiol 1999;180:271-84. (Pubitemid 29297204)
63. Lu Y, Wahl LM. Production of matrix metalloproteinase-9 by activated human monocytes involves a phosphatidylinositol-3 kinase/Akt/IKKalpha/NF-kappaB pathway. J Leukoc Biol 2005;78:259-65. (Pubitemid 40979965)
64. Russell RE, Culpitt SV, DeMatos C, et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002;26:602-9. (Pubitemid 34315869)
65. McMillan JI, Riordan JW, Couser WG, Pollock AS, Lovett DH. Characterization of a glomerular epithelial cell metalloproteinase as matrix metalloproteinase-9 with enhanced expression in a model of membranous nephropathy. J Clin Invest 1996;97:1094-101. (Pubitemid 26070589)
66. Wiehler S, Cuvelier SL, Chakrabarti S, Patel KD. p38 MAP kinase regulates rapid matrix metalloproteinase-9 release from eosinophils. Biochem Biophys Res Commun 2004;315:463-70. (Pubitemid 38183129)
67. Rybakowski JK. Matrix Metalloproteinase-9 (MMP9)-A Mediating Enzyme in Cardiovascular Disease, Cancer, and Neuropsychiatric Disorders. Cardiovasc Psychiatry Neurol 2009;2009:904836.
68. Stracke JO, Fosang AJ, Last K, et al. Matrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP). FEBS Lett 2000;478:52-6. (Pubitemid 30462257)
69. Li W, Machule D, Gao C, DenBesten PK. Activation of recombinant bovine matrix metalloproteinase-20 and its hydrolysis of two amelogenin oligopeptides. Eur J Oral Sci 1999;107:352-9.
70. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69:562-73. (Pubitemid 43139720)
71. Oh J, Takahashi R, Kondo S, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001;107:789-800. (Pubitemid 34033671)
72. Takahashi C, Sheng Z, Horan TP, et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membraneanchored glycoprotein RECK. Proc Natl Acad Sci U S A 1998;95:13221-6. (Pubitemid 28509552)
73. Herman MP, Sukhova GK, Kisiel W, et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest 2001;107:1117-26. (Pubitemid 32422908)
74. Patterson BC, Sang QA. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 1997;272:28823-5. (Pubitemid 27498157)
75. Sasaki T, Gohring W, Mann K, et al. Limited cleavage of extracellular matrix protein BM-40 by matrix metalloproteinases increases its affinity for collagens. J Biol Chem 1997;272:9237-43. (Pubitemid 27154933)
76. Fiore E, Fusco C, Romero P, Stamenkovic I. Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene 2002;21:5213-23. (Pubitemid 34948133)
77. Imai K, Hiramatsu A, Fukushima D, Pierschbacher MD, Okada Y. Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem J 1997;322 ( Pt 3):809-14. (Pubitemid 27135628)
78. Schonbeck U, Mach F, Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 1998;161:3340-6.
79. Ito A, Mukaiyama A, Itoh Y, et al. Degradation of interleukin 1beta by matrix metalloproteinases. J Biol Chem 1996;271:14657-60. (Pubitemid 26194936)
80. Ocana MF, Neubert H. An immunoaffinity liquid chromatography-tandem mass spectrometry assay for the quantitation of matrix metalloproteinase 9 in mouse serum. Anal Biochem;399:202-10.
81. Endo T, Nakabayashi K, Sekiuchi M, Kuroda T, Soejima A, Yamada A. Matrix metalloproteinase-2, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in the peripheral blood of patients with various glomerular diseases and their implication in pathogenetic lesions: study based on an enzyme-linked assay and immunohistochemical staining. Clin Exp Nephrol 2006;10:253-61. (Pubitemid 46012954)
82. Lefkowitz RB, Schmid-Schonbein GW, Heller MJ. Whole blood assay for elastase, chymotrypsin, matrix metalloproteinase-2, and matrix metalloproteinase-9 activity. Anal Chem;82:8251-8.
83. Vine N, Powell JT. Metalloproteinases in degenerative aortic disease. Clin Sci (Lond) 1991;81:233-9.
84. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-503. (Pubitemid 24379627)
85. Galis ZS, Sukhova GK, Libby P. Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J 1995;9:974-80.
86. Chen F, Eriksson P, Hansson GK, et al. Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque. Int J Mol Med 2005;15:57-65.
87. Formato M, Farina M, Spirito R, et al. Evidence for a proinflammatory and proteolytic environment in plaques from endarterectomy segments of human carotid arteries. Arterioscler Thromb Vasc Biol 2004;24:129-35. (Pubitemid 38082423)
88. Luttun A, Lutgens E, Manderveld A, et al. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation 2004;109:1408-14. (Pubitemid 38387828)
89. Johnson C, Galis ZS. Matrix metalloproteinase-2 and-9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol 2004;24:54-60. (Pubitemid 38082411)
90. Galis ZS, Muszynski M, Sukhova GK, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994;75:181-9. (Pubitemid 24187750)
91. Fabunmi RP, Baker AH, Murray EJ, Booth RF, Newby AC. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1,-2, and-3 in rabbit aortic smooth muscle cells. Biochem J 1996;315 ( Pt 1):335-42. (Pubitemid 26113571)
92. Hanemaaijer R, Koolwijk P, le Clercq L, de Vree WJ, van Hinsbergh VW. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumor necrosis factor alpha, interleukin 1 and phorbol ester. Biochem J 1993;296 ( Pt 3):803-9. (Pubitemid 24008200)
93. Davies MJ. Reactive oxygen species, metalloproteinases, and plaque stability. Circulation 1998;97:2382-3. (Pubitemid 28278179)
94. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993;4:1317-26. (Pubitemid 24045761)
95. Papalambros E, Sigala F, Georgopoulos S, et al. Vascular endothelial growth factor and matrix metalloproteinase 9 expression in human carotid atherosclerotic plaques: relationship with plaque destabilization via neovascularization. Cerebrovasc Dis 2004;18:160-5. (Pubitemid 39077853)
96. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993;69:377-81. (Pubitemid 23171108)
97. Loftus IM, Naylor AR, Goodall S, et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke 2000;31:40-7.
98. Kunte H, Kunte G, Busch MA, Weichert W, Ruckert RI, Harms L. Differences in carotid plaque content of macrophages, T cells and MMP-9 between patients with embolic and hemodynamic cerebral ischemia due to symptomatic carotid stenosis. Atherosclerosis;211:456-60.
99. Kalela A, Koivu TA, Sisto T, et al. Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scand J Clin Lab Invest 2002;62:337-42.
100. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases-2 and-9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998;32:368-72. (Pubitemid 28396484)
101. Higo S, Uematsu M, Yamagishi M, et al. Elevation of plasma matrix metalloproteinase-9 in the culprit coronary artery in patients with acute myocardial infarction: clinical evidence from distal protection. Circ J 2005;69:1180-5. (Pubitemid 41382935)
102. Blankenberg S, Rupprecht HJ, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-85. (Pubitemid 36397324)
103. Welsh P, Whincup PH, Papacosta O, et al. Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men. QJM 2008;101:785-91.
104. Brunner S, Kim JO, Methe H. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease. Am J Cardiol;105:429-34.
105. Bittner A, Alcaino H, Castro PF, et al. Matrix metalloproteinase-9 activity is associated to oxidative stress in patients with acute coronary syndrome. Int J Cardiol;143:98-100.
106. Kelly D, Khan SQ, Thompson M, et al. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J 2008;29:2116-24.
107. Squire IB, Evans J, Ng LL, Loftus IM, Thompson MM. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 2004;10:328-33. (Pubitemid 39092685)
108. Webb CS, Bonnema DD, Ahmed SH, et al. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation 2006;114:1020-7. (Pubitemid 44358878)
109. Porter KE, Turner NA. Statins for the prevention of vein graft stenosis: a role for inhibition of matrix metalloproteinase-9. Biochem Soc Trans 2002;30:120-6.
110. Papageorgiou N, Tousoulis D, Antoniades C, Giolis A, Briasoulis A, Stefanadis C. The impact of statin administration in acute coronary syndromes. Hellenic J Cardiol;51:250-61.
111. Tousoulis D, Andreou I, Tentolouris C, et al. Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. Int J Cardiol;145:438-43.
112. Xie P, Cao YS, Su P, Li YH, Gao ZL, Borst MM. Expression of toll-like receptor 4, tumor necrosis factor-alpha, matrix metalloproteinase-9 and effects of benazepril in patients with acute coronary syndromes. Clin Med Insights Cardiol;4:89-93.
113. Murono S, Yoshizaki T, Sato H, Takeshita H, Furukawa M, Pagano JS. Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. Cancer Res 2000;60:2555-61. (Pubitemid 30262452)
114. Lee CZ, Xu B, Hashimoto T, McCulloch CE, Yang GY, Young WL. Doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model. Stroke 2004;35:1715-9. (Pubitemid 38823653)
115. Palomaki GE, Wright DE, Summers AM, et al. Repeated measurement of pregnancy-associated plasma protein-A (PAPP-A) in Down syndrome screening: a validation study. Prenat Diagn 2006;26:730-9. (Pubitemid 44252252)
116. Qin QP, Christiansen M, Pettersson K. Point-of-care time-resolved immunofluorometric assay for human pregnancy-associated plasma protein A: use in first-trimester screening for Down syndrome. Clin Chem 2002;48:473-83. (Pubitemid 34174578)
117. Lawrence JB, Oxvig C, Overgaard MT, et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci U S A 1999;96:3149-53. (Pubitemid 29148859)
118. Kalli KR, Chen BK, Bale LK, et al. Pregnancy-associated plasma protein-A (PAPP-A) expression and insulin-like growth factor binding protein-4 protease activity in normal and malignant ovarian surface epithelial cells. Int J Cancer 2004;110:633-40. (Pubitemid 38746020)
119. Chen BK, Leiferman KM, Pittelkow MR, Overgaard MT, Oxvig C, Conover CA. Localization and regulation of pregnancy-associated plasma protein a expression in healing human skin. J Clin Endocrinol Metab 2003;88:4465-71. (Pubitemid 37153758)
120. Qin X, Wergedal JE, Rehage M, et al. Pregnancy-associated plasma protein-A increases osteoblast proliferation in vitro and bone formation in vivo. Endocrinology 2006;147:5653-61. (Pubitemid 44833482)
121. Bayes-Genis A, Conover CA, Overgaard MT, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001;345:1022-9.
122. Qin QP, Kokkala S, Lund J, Tamm N, Voipio-Pulkki LM, Pettersson K. Molecular distinction of circulating pregnancy-associated plasma protein A in myocardial infarction and pregnancy. Clin Chem 2005;51:75-83. (Pubitemid 40028321)
123. Conover CA, Harrington SC, Bale LK. Differential regulation of pregnancy associated plasma protein-A in human coronary artery endothelial cells and smooth muscle cells. Growth Horm IGF Res 2008;18:213-20. (Pubitemid 351479925)
124. You L, Li L, Zhang F, Xu Q, Ren J. A pilot study of the clinical relevance of the relationship between the serum level of pregnancy-associated plasma protein A and the degree of acute coronary syndrome. J Int Med Res;38:625-32.
125. Iversen KK, Dalsgaard M, Teisner AS, et al. Pregnancy-associated plasma protein-A, a marker for outcome in patients suspected for acute coronary syndrome. Clin Biochem;43:851-7.
126. Heeschen C, Dimmeler S, Fichtlscherer S, et al. Prognostic value of placental growth factor in patients with acute chest pain. JAMA 2004;291:435-41. (Pubitemid 38129747)
127. Lund J, Qin QP, Ilva T, et al. Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation 2003;108:1924-6. (Pubitemid 37296534)
128. Mei WY, Du ZM, Zhao Q, et al. Pregnancy-associated plasma protein predicts outcomes of percutaneous coronary intervention in patients with non-ST-elevation acute coronary syndrome. Heart Lung.
129. Cosin-Sales J, Kaski JC, Christiansen M, et al. Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris. Eur Heart J 2005;26:2093-8. (Pubitemid 41407989)
130. Iversen KK, Teisner B, Winkel P, et al. Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: A prognostic study within the CLARICOR Trial. Atherosclerosis.
131. Iversen KK, Teisner AS, Teisner B, et al. Pregnancy associated plasma protein A, a novel, quick, and sensitive marker in ST-elevation myocardial infarction. Am J Cardiol 2008;101:1389-94.
132. Lund J, Qin QP, Ilva T, et al. Pregnancy-associated plasma protein A: a biomarker in acute ST-elevation myocardial infarction (STEMI). Ann Med 2006;38:221-8. (Pubitemid 43675587)
133. Biasillo G, Leo M, Della Bona R, Biasucci LM. Inflammatory biomarkers and coronary heart disease: from bench to bedside and back. Intern Emerg Med;5:225-33.
134. Anand SX, Viles-Gonzalez JF, Badimon JJ, Cavusoglu E, Marmur JD. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 2003;90:377-84. (Pubitemid 37138761)
135. Spriggs MK, Fanslow WC, Armitage RJ, Belmont J. The biology of the human ligand for CD40. J Clin Immunol 1993;13:373-80. (Pubitemid 23334135)
136. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001;58:4-43. (Pubitemid 32143961)
137. Tousoulis D, Antoniades C, Nikolopoulou A, et al. Interaction between cytokines and sCD40L in patients with stable and unstable coronary syndromes. Eur J Clin Invest 2007;37:623-8. (Pubitemid 47063099)
138. Chen Y, Chen J, Xiong Y, et al. Internalization of CD40 regulates its signal transduction in vascular endothelial cells. Biochem Biophys Res Commun 2006;345:106-17.
139. Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 1996;14:591-617. (Pubitemid 26130658)
140. Ludewig B, Henn V, Schroder JM, Graf D, Kroczek RA. Induction, regulation, and function of soluble TRAP (CD40 ligand) during interaction of primary CD4+ CD45RA+ T cells with dendritic cells. Eur J Immunol 1996;26:3137-43. (Pubitemid 26411524)
141. Wykes M, Poudrier J, Lindstedt R, Gray D. Regulation of cytoplasmic, surface and soluble forms of CD40 ligand in mouse B cells. Eur J Immunol 1998;28:548-59. (Pubitemid 28101732)
142. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 2003;107:1123-8. (Pubitemid 36297203)
143. Giunta B, Rezai-Zadeh K, Tan J. Impact of the CD40-CD40L dyad in Alzheimer's disease. CNS Neurol Disord Drug Targets;9:149-55.
144. Kebapcilar L, Sari I, Renkal AH, et al. The influence of Helicobacter pylori eradication on leptin, soluble CD40 ligand, oxidative stress and body composition in patients with peptic ulcer disease. Intern Med 2009;48:2055-9.
145. Giunta B, Figueroa KP, Town T, Tan J. Soluble Cd40 Ligand in Dementia. Drugs Future 2009;34:333-40.
146. Lutgens E, Gorelik L, Daemen MJ, et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999;5:1313-6. (Pubitemid 29535611)
147. Lutgens E, Cleutjens KB, Heeneman S, Koteliansky VE, Burkly LC, Daemen MJ. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci U S A 2000;97:7464-9. (Pubitemid 30431486)
148. Schonbeck U, Sukhova GK, Shimizu K, Mach F, Libby P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A 2000;97:7458-63. (Pubitemid 30431485)
149. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009;54:669-77.
150. Wagner AH, Guldenzoph B, Lienenluke B, Hecker M. CD154/CD40-mediated expression of CD154 in endothelial cells: consequences for endothelial cell-monocyte interaction. Arterioscler Thromb Vasc Biol 2004;24:715-20. (Pubitemid 38451609)
151. Stout RD, Suttles J. The many roles of CD40 in cell-mediated inflammatory responses. Immunol Today 1996;17:487-92.
152. Schonbeck U, Mach F, Bonnefoy JY, Loppnow H, Flad HD, Libby P. Ligation of CD40 activates interleukin 1beta-converting enzyme (caspase-1) activity in vascular smooth muscle and endothelial cells and promotes elaboration of active interleukin 1beta. J Biol Chem 1997;272:19569-74. (Pubitemid 27337759)
153. Antoniades C, Bakogiannis C, Tousoulis D, Demosthenous M, Marinou K, Stefanadis C. Platelet activation in atherogenesis associated with low-grade inflammation. Inflamm Allergy Drug Targets;9:334-45.
154. Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N, Schonbeck U. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem 2002;277:25032-9. (Pubitemid 34951807)
155. Urbich C, Dernbach E, Aicher A, Zeiher AM, Dimmeler S. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 2002;106:981-6. (Pubitemid 34925334)
156. Cipollone F, Chiarelli F, Davi G, et al. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 2005;48:1216-24. (Pubitemid 40909659)
157. Loskog A, Ninalga C, Totterman TH. Dendritic cells engineered to express CD40L continuously produce IL12 and resist negative signals from Tr1/Th3 dominated tumors. Cancer Immunol Immunother 2006;55:588-97.
158. Horton DB, Libby P, Schonbeck U. Ligation of CD40 onvascular smooth muscle cells mediates loss of interstitial collagen via matrix metalloproteinase activity. Ann N Y Acad Sci 2001;947:329-36. (Pubitemid 34059930)
159. Tousoulis D, Paroutoglou IP, Papageorgiou N, Charakida M, Stefanadis C. Recent therapeutic approaches to platelet activation in coronary artery disease. Pharmacol Ther;127:108-20.
160. Aukrust P, Muller F, Ueland T, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999;100:614-20.
161. Ko YG, Jung JH, Park S, et al. Inflammatory and vasoactive factors in the aspirate from the culprit coronary artery of patients with acute myocardial infarction. Int J Cardiol 2006;112:66-71. (Pubitemid 44247179)
162. Wang Y, Li L, Tan HW, et al. Transcoronary concentration gradient of sCD40L and hsCRP in patients with coronary heart disease. Clin Cardiol 2007;30:86-91.
163. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003;348:1104-11. (Pubitemid 36337321)
164. Plaikner M, Peer A, Falkensammer G, et al. Lack of association of soluble CD40 ligand with the presence of acute myocardial infarction or ischemic stroke in the emergency department. Clin Chem 2009;55:175-8.
165. Martins TB, Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Roberts WL. Risk factor analysis of plasma cytokines in patients with coronary artery disease by a multiplexed fluorescent immunoassay. Am J Clin Pathol 2006;125:906-13. (Pubitemid 43801541)
166. Kaski JC, Fernandez-Berges DJ, Consuegra-Sanchez L, et al. A comparative study of biomarkers for risk prediction in acute coronary syndrome-Results of the SIESTA (Systemic Inflammation Evaluation in non-ST-elevation Acute coronary syndrome) study. Atherosclerosis;212:636-43.
167. Olenchock BA, Wiviott SD, Murphy SA, et al. Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16. J Thromb Thrombolysis 2008;26:79-84.
168. Varo N, Nuzzo R, Natal C, Libby P, Schonbeck U. Influence of preanalytical and analytical factors on soluble CD40L measurements. Clin Sci (Lond) 2006;111:341-7. (Pubitemid 44690192)
169. Wenzel F, Baertl A, Zimmermann N, et al. Different behaviour of soluble CD40L concentrations can be reflected by variations of preanalytical conditions. Clin Hemorheol Microcirc 2008;39:417-22. (Pubitemid 352040027)
170. Antoniades C, Tousoulis D, Vasiliadou C, Stefanadi E, Marinou K, Stefanadis C. Genetic polymorphisms of platelet glycoprotein Ia and the risk for premature myocardial infarction: effects on the release of sCD40L during the acute phase of premature myocardial infarction. J Am Coll Cardiol 2006;47:1959-66.
171. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A 1991;88:9267-71. (Pubitemid 21915612)
172. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-8.
173. Hauser S, Weich HA. A heparin-binding form of placenta growth factor (PlGF-2) is expressed in human umbilical vein endothelial cells and in placenta. Growth Factors 1993;9:259-68. (Pubitemid 24034347)
174. Migdal M, Huppertz B, Tessler S, et al. Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem 1998;273:22272-8. (Pubitemid 28399784)
175. Gluzman-Poltorak Z, Cohen T, Herzog Y, Neufeld G. Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165. J Biol Chem 2000;275:29922.
176. Persico MG, Vincenti V, DiPalma T. Structure, expression and receptorbinding properties of placenta growth factor (PlGF). Curr Top Microbiol Immunol 1999;237:31-40. (Pubitemid 128767693)
177. Beck H, Acker T, Puschel AW, Fujisawa H, Carmeliet P, Plate KH. Cell type-specific expression of neuropilins in an MCA-occlusion model in mice suggests a potential role in post-ischemic brain remodeling. J Neuropathol Exp Neurol 2002;61:339-50. (Pubitemid 34266785)
178. Iyer S, Acharya KR. Role of placenta growth factor in cardiovascular health. Trends Cardiovasc Med 2002;12:128-34. (Pubitemid 34462183)
179. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8:831-40.
180. Roncal C, Buysschaert I, Gerdes N, et al. Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions. Cardiovasc Res;86:29-36.
181. Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003;1:1356-70.
182. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 2001;276:7614-20.
183. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001;7:425-9. (Pubitemid 32298544)
184. Lemstrom KB, Krebs R, Nykanen AI, et al. Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. Circulation 2002;105:2524-30. (Pubitemid 34568975)
185. Zhao Q, Egashira K, Inoue S, et al. Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation 2002;105:1110-5. (Pubitemid 34212623)
186. Lenderink T, Heeschen C, Fichtlscherer S, et al. Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes. J Am Coll Cardiol 2006;47:307-11. (Pubitemid 43063247)
187. Apple FS, Pearce LA, Chung A, Ler R, Murakami MM. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem 2007;53:874-81. (Pubitemid 46744243)
188. Cassidy A, Chiuve SE, Manson JE, Rexrode KM, Girman CJ, Rimm EB. Potential role for plasma placental growth factor in predicting coronary heart disease risk in women. Arterioscler Thromb Vasc Biol 2009;29:134-9.
189. Mockel M, Danne O, Muller R, et al. Development of an optimized multimarker strategy for early risk assessment of patients with acute coronary syndromes. Clin Chim Acta 2008;393:103-9.
190. Doweiko JP, Nompleggi DJ. Role of albumin in human physiology and pathophysiology. JPEN J Parenter Enteral Nutr 1991;15:207-11.
191. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985;312:159-63. (Pubitemid 15192863)
192. Cobbe SM, Poole-Wilson PA. The time of onset and severity of acidosis in myocardial ischaemia. J Mol Cell Cardiol 1980;12:745-60. (Pubitemid 10056516)
193. Berenshtein E, Mayer B, Goldberg C, Kitrossky N, Chevion M. Patterns of mobilization of copper and iron following myocardial ischemia: possible predictive criteria for tissue injury. J Mol Cell Cardiol 1997;29:3025-34. (Pubitemid 27510769)
194. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 2000;19:311-5.
195. Anwaruddin S, Januzzi JL, Jr., Baggish AL, Lewandrowski EL, Lewandrowski KB. Ischemia-modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting. Am J Clin Pathol 2005;123:140-5. (Pubitemid 40066181)
196. Collinson PO, Gaze DC, Bainbridge K, et al. Utility of admission cardiac troponin and "Ischemia Modified Albumin" measurements for rapid evaluation and rule out of suspected acute myocardial infarction in the emergency department. Emerg Med J 2006;23:256-61. (Pubitemid 44295312)
197. Sinha MK, Roy D, Gaze DC, Collinson PO, Kaski JC. Role of "Ischemia modified albumin", a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg Med J 2004;21:29-34. (Pubitemid 38165479)
198. Liyan C, Jie Z, Yonghua W, Xiaozhou H. Assay of ischemia-modified albumin and C-reactive protein for early diagnosis of acute coronary syndromes. J Clin Lab Anal 2008;22:45-9. (Pubitemid 351272480)
199. Shen XL, Xing C, Han LL, et al. [Diagnostic value of ischemia-modified albumin in patients with acute coronary syndrome]. Zhonghua Xin Xue Guan Bing Za Zhi 2007;35:814-7.
200. Shen XL, Lin CJ, Han LL, Lin L, Pan L, Pu XD. Assessment of ischemiamodified albumin levels for emergency room diagnosis of acute coronary syndrome. Int J Cardiol.
201. Hjortshoj S, Kristensen SR, Ravkilde J. Diagnostic value of ischemiamodified albumin in patients with suspected acute coronary syndrome. Am J Emerg Med;28:170-6.
202. Charpentier S, Ducasse JL, Cournot M, et al. Clinical assessment of ischemia-modified albumin and heart fatty acid-binding protein in the early diagnosis of non-ST-elevation acute coronary syndrome in the emergency department. Acad Emerg Med;17:27-35.
203. Van Belle E, Dallongeville J, Vicaut E, Degrandsart A, Baulac C, Montalescot G. Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study. Am Heart J;159:570-6.
204. Quiles J, Roy D, Gaze D, et al. Relation of ischemia-modified albumin (IMA) levels following elective angioplasty for stable angina pectoris to duration of balloon-induced myocardial ischemia. Am J Cardiol 2003;92:322-4. (Pubitemid 36897723)
205. Sinha MK, Gaze DC, Tippins JR, Collinson PO, Kaski JC. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation 2003;107:2403-5. (Pubitemid 36605219)
206. Peacock F, Morris DL, Anwaruddin S, et al. Meta-analysis of ischemiamodified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J 2006;152:253-62. (Pubitemid 44093396)
207. Danne O, Mockel M. Choline in acute coronary syndrome: an emerging biomarker with implications for the integrated assessment of plaque vulnerability. Expert Rev Mol Diagn;10:159-71.
208. Gomez-Munoz A, Martens JS, Steinbrecher UP. Stimulation of phospholipase D activity by oxidized LDL in mouse peritoneal macrophages. Arterioscler Thromb Vasc Biol 2000;20:135-43. (Pubitemid 30048356)
209. Williger BT, Ho WT, Exton JH. Phospholipase D mediates matrix metalloproteinase-9 secretion in phorbol ester-stimulated human fibrosarcoma cells. J Biol Chem 1999;274:735-8.
210. Chiang TM. Activation of phospholipase D in human platelets by collagen and thrombin and its relationship to platelet aggregation. Biochim Biophys Acta 1994;1224:147-55. (Pubitemid 24326793)
211. Martinson EA, Scheible S, Marx-Grunwitz A, Presek P. Secreted ADP plays a central role in thrombin-induced phospholipase D activation in human platelets. Thromb Haemost 1998;80:976-81. (Pubitemid 28556702)
212. Haslam RJ, Coorssen JR. Evidence that activation of phospholipase D can mediate secretion from permeabilized platelets. Adv Exp Med Biol 1993;344:149-64.
213. Smyth SS, Hillery CA, Parise LV. Fibrinogen binding to purified platelet glycoprotein IIb-IIIa (integrin alpha IIb beta 3) is modulated by lipids. J Biol Chem 1992;267:15568-77.
214. Spector AA. Plaque rupture, lysophosphatidic acid, and thrombosis. Circulation 2003;108:641-3. (Pubitemid 36999242)
215. Rother E, Brandl R, Baker DL, et al. Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation 2003;108:741-7. (Pubitemid 36999261)
216. Body R, Griffith CA, Keevil B, et al. Choline for diagnosis and prognostication of acute coronary syndromes in the Emergency Department. Clin Chim Acta 2009;404:89-94.
217. Danne O, Mockel M, Lueders C, et al. Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. Am J Cardiol 2003;91:1060-7. (Pubitemid 36514920)
218. LeLeiko RM, Vaccari CS, Sola S, et al. Usefulness of elevations in serum choline and free F2)-isoprostane to predict 30-day cardiovascular outcomes in patients with acute coronary syndrome. Am J Cardiol 2009;104:638-43.
219. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50:e1-e157.
220. Morrow DA, Cannon CP, Jesse RL, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem 2007;53:552-74. (Pubitemid 46580223)
221. Pelsers MM, Hanhoff T, Van der Voort D, et al. Brain-and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility. Clin Chem 2004;50:1568-75. (Pubitemid 39121225)
222. Glatz JF, van der Vusse GJ, Simoons ML, Kragten JA, van Dieijen-Visser MP, Hermens WT. Fatty acid-binding protein and the early detection of acute myocardial infarction. Clin Chim Acta 1998;272:87-92. (Pubitemid 28179620)
223. Schaap FG, Binas B, Danneberg H, van der Vusse GJ, Glatz JF. Impaired long-chain fatty acid utilization by cardiac myocytes isolated from mice lacking the heart-type fatty acid binding protein gene. Circ Res 1999;85:329-37. (Pubitemid 29398865)
224. Gururajan P, Gurumurthy P, Nayar P, Srinivasa Nageswara Rao G, Babu S, Cherian KM. Heart fatty acid binding protein (H-FABP) as a diagnostic biomarker in patients with acute coronary syndrome. Heart Lung Circ;19:660-4.
225. Zschiesche W, Kleine AH, Spitzer E, Veerkamp JH, Glatz JF. Histochemical localization of heart-type fatty-acid binding protein in human and murine tissues. Histochem Cell Biol 1995;103:147-56.
226. Maatman RG, van de Westerlo EM, van Kuppevelt TH, Veerkamp JH. Molecular identification of the liver-and the heart-type fatty acid-binding proteins in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction. Biochem J 1992;288 ( Pt 1):285-90.
227. O'Donoghue M, de Lemos JA, Morrow DA, et al. Prognostic utility of hearttype fatty acid binding protein in patients with acute coronary syndromes. Circulation 2006;114:550-7. (Pubitemid 44199644)
228. Valle HA, Riesgo LG, Bel MS, Gonzalo FE, Sanchez MS, Oliva LI. Clinical assessment of heart-type fatty acid binding protein in early diagnosis of acute coronary syndrome. Eur J Emerg Med 2008;15:140-4. (Pubitemid 351643488)
229. Haltern G, Peiniger S, Bufe A, Reiss G, Gulker H, Scheffold T. Comparison of usefulness of heart-type fatty acid binding protein versus cardiac troponin T for diagnosis of acute myocardial infarction. Am J Cardiol;105:1-9.
230. Liao J, Chan CP, Cheung YC, et al. Human heart-type fatty acid-binding protein for on-site diagnosis of early acute myocardial infarction. Int J Cardiol 2009;133:420-3.
231. Mad P, Domanovits H, Fazelnia C, et al. Human heart-type fatty-acidbinding protein as a point-of-care test in the early diagnosis of acute myocardial infarction. QJM 2007;100:203-10. (Pubitemid 47061688)
232. Viswanathan K, Kilcullen N, Morrell C, et al. Heart-type fatty acid-binding protein predicts long-term mortality and re-infarction in consecutive patients with suspected acute coronary syndrome who are troponin-negative. J Am Coll Cardiol;55:2590-8.
233. Kilcullen N, Viswanathan K, Das R, et al. Heart-type fatty acid-binding protein predicts long-term mortality after acute coronary syndrome and identifies high-risk patients across the range of troponin values. J Am Coll Cardiol 2007;50:2061-7. (Pubitemid 350087577)
234. Braunwald E, Jones RH, Mark DB, et al. Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. Circulation 1994;90:613-22.
235. Entman ML, Bornet EP, Van Winkle WB, Goldstein MA, Schwartz A. Association of glycogenolysis with cardiac sarcoplasmic reticulum: II. Effect of glycogen depletion, deoxycholate solubilization and cardiac ischemia: evidence for a phorphorylase kinase membrane complex. J Mol Cell Cardiol 1977;9:515-28. (Pubitemid 8145968)
236. Newgard CB, Hwang PK, Fletterick RJ. The family of glycogen phosphorylases: structure and function. Crit Rev Biochem Mol Biol 1989;24:69-99.
237. Kato K, Shimizu A, Kurobe N, Takashi M, Koshikawa T. Human brain-type glycogen phosphorylase: quantitative localization in human tissues determined with an immunoassay system. J Neurochem 1989;52:1425-32. (Pubitemid 19109491)
238. Meyer F, Heilmeyer LM, Jr., Haschke RH, Fischer EH. Control of phosphorylase activity in a muscle glycogen particle. I. Isolation and characterization of the protein-glycogen complex. J Biol Chem 1970;245:6642-8.
239. Krause EG, Rabitzsch G, Noll F, Mair J, Puschendorf B. Glycogen phosphorylase isoenzyme BB in diagnosis of myocardial ischaemic injury and infarction. Mol Cell Biochem 1996;160-161:289-95. (Pubitemid 26336365)
240. Peetz D, Post F, Schinzel H, et al. Glycogen phosphorylase BB in acute coronary syndromes. Clin Chem Lab Med 2005;43:1351-8.
241. Mair J, Puschendorf B, Smidt J, et al. Early release of glycogen phosphorylase in patients with unstable angina and transient ST-T alterations. Br Heart J 1994;72:125-7. (Pubitemid 24251461)
242. Rabitzsch G, Mair J, Lechleitner P, et al. Immunoenzymometric assay of human glycogen phosphorylase isoenzyme BB in diagnosis of ischemic myocardial injury. Clin Chem 1995;41:966-78.
243. McCann CJ, Glover BM, Menown IB, et al. Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T. Eur Heart J 2008;29:2843-50.
244. McCann CJ, Glover BM, Menown IB, et al. Prognostic value of a multimarker approach for patients presenting to hospital with acute chest pain. Am J Cardiol 2009;103:22-8.
245. Katan M, Christ-Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly;140:w13101.
246. Katan M, Morgenthaler N, Widmer I, et al. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett 2008;29:341-6.
247. Morgenthaler NG, Muller B, Struck J, Bergmann A, Redl H, Christ-Crain M. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007;28:219-26. (Pubitemid 47220835)
248. Muller B, Morgenthaler N, Stolz D, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007;37:145-52. (Pubitemid 46066494)
249. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007;131:1058-67. (Pubitemid 46608707)
250. Katan M, Fluri F, Morgenthaler NG, et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 2009;66:799-808.
251. Khan SQ, Dhillon OS, O'Brien RJ, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 2007;115:2103-10. (Pubitemid 46659061)
252. Reichlin T, Hochholzer W, Stelzig C, et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 2009;54:60-8.
253. Voors AA, von Haehling S, Anker SD, et al. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 2009;30:1187-94.
254. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:112-9. (Pubitemid 43032474)
255. de Kruif MD, Lemaire LC, Giebelen IA, et al. The influence of corticosteroids on the release of novel biomarkers in human endotoxemia. Intensive Care Med 2008;34:518-22. (Pubitemid 351623033)
256. Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 2009;116:257-63.
257. Chang LT, Chua S, Sheu JJ, et al. Level and prognostic value of serum myeloperoxidase in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ J 2009;73:726-31.
258. Cavusoglu E, Ruwende C, Eng C, et al. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol 2007;99:1364-8. (Pubitemid 46686633)
259. Esporcatte R, Rey HC, Rangel FO, et al. Predictive value of myeloperoxidase to identify high risk patients admitted to the hospital with acute chest pain. Arq Bras Cardiol 2007;89:377-84.
260. Roman RM, Camargo PV, Borges FK, Rossini AP, Polanczyk CA. Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients. Coron Artery Dis;21:129-36.
261. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001;141:211-7. (Pubitemid 32128725)
262. Manginas A, Bei E, Chaidaroglou A, et al. Peripheral levels of matrix metalloproteinase-9, interleukin-6, and C-reactive protein are elevated in patients with acute coronary syndromes: correlations with serum troponin I. Clin Cardiol 2005;28:182-6. (Pubitemid 40471698)
263. Shu J, Ren N, Du JB, Zhang M, Cong HL, Huang TG. Increased levels of interleukin-6 and matrix metalloproteinase-9 are of cardiac origin in acute coronary syndrome. Scand Cardiovasc J 2007;41:149-54. (Pubitemid 46784845)
264. Qin Q, Zhao BR, Mao YM, et al. [Association of matrix metalloproteinase-9 and platelet membrane glycoprotein VI polymorphisms with acute coronary syndrome]. Zhonghua Xin Xue Guan Bing Za Zhi 2005;33:622-6. (Pubitemid 41371809)
265. Christenson RH, Duh SH, Sanhai WR, et al. Characteristics of an Albumin Cobalt Binding Test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem 2001;47:464-70. (Pubitemid 32222460)
266. Liyan C, Jie Z, Xiaozhou H. Prognostic value of combination of heart-type fatty acid-binding protein and ischemia-modified albumin in patients with acute coronary syndromes and normal troponin T values. J Clin Lab Anal 2009;23:14-8.
267. Aparci M, Kardesoglu E, Ozmen N, et al. Prognostic significance of ischemia-modified albumin in patients with acute coronary syndrome. Coron Artery Dis 2007;18:367-73. (Pubitemid 47186837)
268. Lee YW, Kim HJ, Cho YH, Shin HB, Choi TY, Lee YK. Application of albumin-adjusted ischemia modified albumin index as an early screening marker for acute coronary syndrome. Clin Chim Acta 2007;384:24-7. (Pubitemid 47247405)
269. Liu ZY, Zhang JY, Sun TW, Zhang YJ, Zhang L, Wang LX. Levels of pregnancy-associated plasma protein A in patients with coronary artery disease. Clin Invest Med 2008;31:E85-9.
270. Hajek P, Macek M, Hladikova M, et al. Pregnancy-associated plasma protein A and proform eosinophilic major basic protein in the detection of different types of coronary artery disease. Physiol Res 2008;57:23-32.
271. Laterza OF, Cameron SJ, Chappell D, Sokoll LJ, Green GB. Evaluation of pregnancy-associated plasma protein A as a prognostic indicator in acute coronary syndrome patients. Clin Chim Acta 2004;348:163-9. (Pubitemid 39209015)
272. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez M, Ferrer J, Vargas M. Circulating pregnancy-associated plasma protein A is not an early marker of acute myocardial infarction. Clin Biochem 2005;38:180-2. (Pubitemid 40092462)
273. Ruzgar O, Bilge AK, Bugra Z, et al. The use of human heart-type fatty acidbinding protein as an early diagnostic biochemical marker of myocardial necrosis in patients with acute coronary syndrome, and its comparison with troponin-T and creatine kinase-myocardial band. Heart Vessels 2006;21:309-14. (Pubitemid 44873630)
274. Cavus U, Coskun F, Yavuz B, et al. Heart-type, fatty-acid binding protein can be a diagnostic marker in acute coronary syndromes. J Natl Med Assoc 2006;98:1067-70. (Pubitemid 44167769)
275. Ishii J, Ozaki Y, Lu J, et al. Prognostic value of serum concentration of heart-type fatty acid-binding protein relative to cardiac troponin T on admission in the early hours of acute coronary syndrome. Clin Chem 2005;51:1397-404. (Pubitemid 41060871)
276. Wang J, Zhang S, Jin Y, Qin G, Yu L, Zhang J. Elevated levels of plateletmonocyte aggregates and related circulating biomarkers in patients with acute coronary syndrome. Int J Cardiol 2007;115:361-5. (Pubitemid 46185636)
277. Malarstig A, Lindahl B, Wallentin L, Siegbahn A. Soluble CD40L levels are regulated by the-3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome. Arterioscler Thromb Vasc Biol 2006;26:1667-73. (Pubitemid 44288999)
278. Garlichs CD, Eskafi S, Raaz D, et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 2001;86:649-55. (Pubitemid 33086881)
279. Peng DQ, Zhao SP, Li YF, Li J, Zhou HN. Elevated soluble CD40 ligand is related to the endothelial adhesion molecules in patients with acute coronary syndrome. Clin Chim Acta 2002;319:19-26. (Pubitemid 34261008)